Drug Profile
Research programme: chronic obstructive pulmonary disease therapeutics - Dr. Reddy's Laboratories/Pulmagen Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Argenta Discovery; Dr Reddys Laboratories
- Developer Dr Reddys Laboratories; Pulmagen Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
- 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV
- 27 Nov 2007 The first candidate drug to proceed into preclinical development has been selected from this programme